FEDERAL RESERVE SYSTEM

Notice of Proposals To Engage in or To Acquire Companies Engaged in Permissible Nonbanking Activities

The companies listed in this notice have given notice under section 225.28 of the Bank Holding Company Act (12 U.S.C. 1843) (BHC Act) and Regulation Y, (12 CFR part 225) to engage de novo, or to acquire or control voting securities or assets of a company, including the companies listed below, that engages either directly or through a subsidiary or other company, in a nonbanking activity that is listed in §225.28 of Regulation Y (12 CFR 225.28) or that the Board has determined by Order to be closely related to banking and permissible for bank holding companies. Unless otherwise noted, these activities will be conducted throughout the United States. Each notice is available for inspection at the Federal Reserve Bank indicated. The notice also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether the proposal complies with the standards of section 4 of the BHC Act.

Unless otherwise noted, comments regarding the applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than March 1, 2013. A. Federal Reserve Bank of New York (Ivan Hurwitz, Vice President) 33 Liberty Street, New York, New York 10045–0001:
1. Investors Bancorp, MHC and Investors Bancorp, Inc., both in Short Hills, New Jersey, to acquire Roma Financial Corporation MHC, and Roma Financial Corporation, both in Robbinsville, New Jersey, and indirectly acquire Roma Bank, Robbinsville, New Jersey, and RomAsia Bank, South Brunswick Township, New Jersey, and thereby engage in operating savings associations, pursuant to section 225.28(b)(4)(ii).

Michael J. Lewandowski, Assistant Secretary of the Board.
[FR Doc. 2013–02351 Filed 2–1–13; 8:45 am]
BILLING CODE 6210–01–P

GOVERNMENT ACCOUNTABILITY OFFICE

Health Information Technology Policy Committee Nomination Letters

AGENCY: Government Accountability Office (GAO).

ACTION: Notice on letters of nomination of candidates.

SUMMARY: The American Recovery and Reinvestment Act of 2009 (ARRA) established the Health Information Technology Policy Committee (Health IT Policy Committee) and gave the Comptroller General responsibility for appointing 13 of its 20 members.

As the result of terms ending in April 2013, GAO is accepting nominations of individuals for two openings on the committee in the following categories of representation or expertise required in ARRA: advocate for patients or consumers, and a member from a labor organization representing health care workers. For appointments to the HIT Policy committee to be made by April 1, 2013 in these categories, I am announcing the following: Letters of nomination and resumes should be submitted between February 1 and 22, 2013 to ensure adequate opportunity for review and consideration of nominees.

ADDRESSES: GAO: HITCommittee@gao.gov; GAO: 441 G Street NW., Washington, DC 20548.


Gene L. Dodaro, Comptroller General of the United States.
[FR Doc. 2013–02104 Filed 2–1–13; 8:45 am]
BILLING CODE 1610–02–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Draft Guidance for Industry on Enrichment Strategies for Clinical Trials To Support Approval of Human Drugs and Biological Products; Extension of Comment Period

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; extension of comment period.

SUMMARY: The Food and Drug Administration (FDA) is extending the comment period for the draft guidance for industry entitled “Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs and Biological Products” that appeared in the Federal Register of December 17, 2012 (77 FR 74670). In the document, FDA announced the availability of this draft guidance and explained that the comment period would close on February 15, 2013. The Agency is taking this action to allow interested persons additional time to submit comments.

DATES: Although you can comment on any guidance at any time (see 21 CFR 10.115(g)(5)), to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance, submit either electronic or written comments on the draft guidance by March 18, 2013.

ADDRESSES: Submit electronic comments to http://www.regulations.gov. Submit written comments to the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Identify comments with the docket number.